Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has taken a significant step forward in the development of its lead drug candidate ONC010 by engaging Nanosoft Polymers for polymer process development and analytical characterization activities. The company announced that Nanosoft will work on polymer synthesis optimization, characterization methodology development, molecular weight assessment, purification strategy refinement, and manufacturing scalability assessments. These efforts are part of Onco-Innovations’ broader chemistry, manufacturing and controls (CMC) strategy for ONC010, a nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor.
The collaboration is designed to establish a scalable, reproducible, and analytically characterized polymer platform that will support future formulation, manufacturing, regulatory, and clinical development activities. Onco-Innovations noted that Nanosoft’s expertise in polymer science and nanoparticle drug delivery is expected to strengthen the technical foundation of the ONC010 platform and facilitate readiness for Good Manufacturing Practice (GMP) manufacturing. The full press release detailing the announcement is available at https://nnw.fm/BeSoS.
ONC010 is a novel therapeutic that targets solid tumors by inhibiting PNKP, an enzyme involved in DNA repair. By formulating the inhibitor into nanoparticles, Onco-Innovations aims to improve drug delivery and efficacy. The company has secured an exclusive worldwide license to patented technology underlying this approach. The current CMC activities are critical for advancing ONC010 through preclinical development and toward clinical trials, as they ensure that the manufacturing process is robust and reproducible.
The partnership with Nanosoft Polymers underscores Onco-Innovations’ commitment to rigorous technical development. The company’s focus on oncology aligns with its mission to pursue prevention and treatment of cancer through pioneering research and innovative solutions. For investors and stakeholders, this development signals progress in the product pipeline and a move toward regulatory milestones. The latest news and updates regarding ONNVF can be found in the company’s newsroom at https://nnw.fm/ONNVF.
This announcement comes at a time when nanoparticle-based drug delivery systems are gaining traction in oncology due to their potential to enhance therapeutic index and reduce side effects. By addressing manufacturing challenges early, Onco-Innovations is positioning itself to capitalize on these trends. The successful development of a scalable polymer platform could accelerate the timeline for ONC010 and potentially lead to new treatment options for patients with solid tumors.
